Critical Care News

Treatment with baricitinib reduced mortality in critically ill patients with COVID-19 receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, researchers reported in The Lancet Respiratory Medicine.

One-fifth of patients with chronic medical conditions who received two doses of an mRNA COVID-19 vaccine had insufficient antibody levels at least 14 days after the second dose, researchers reported in Chest.

In this episode, I sit down with Hassan Khouli, MD, to discuss his personal and professional journey into medicine, keeping hope in the midst of the pandemic, and the importance of human connection with both patients and colleagues.

National lung cancer screening rates remained low and unchanged from 2019 to 2020, but rates significantly improved in 19 U.S. states despite the COVID-19 pandemic, according to data published in Chest.

In a single-center case series published in JAMA, survival after lung transplant was 100% among 30 patients with COVID-19-associated acute respiratory distress syndrome.

Of more than 3,000 lung transplants performed in the U.S. from August 2020 to Sept. 30, 2021, 7% were performed to treat severe, irreversible lung damage caused by COVID-19, researchers reported in The New England Journal of Medicine.

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic.

SARS-CoV-2 infection, even in asymptomatic cases, can lead to a broad autoantibody response that lasts beyond recovery from infection, according to findings published in the Journal of Translational Medicine.

Health care costs remained high for Medicare beneficiaries with common chronic conditions for which brand-name medications without generic alternatives were recommended, according to findings published in JAMA Internal Medicine.

Sodium-glucose cotransporter 2 inhibitors are an effective class of drugs for improving morbidity and mortality in patients with established atherosclerotic CVD or cardiovascular risk factors, researchers reported.